May 19, 2014 | Israeli company Enlivex Therapeutics has raised $7 million in a convertible loan from a group of investors. Enlivex, a portfolio company of Hadasit Bio Holdings, is developing cell immunotherapy treatments for Graft versus Host Disease.
Related posts
Israel's Top Hospital Unveils Program To Promote HealthTech Startups
September 12, 2024
Battery Startup Announces Superfast Charging For Electric Vehicles
September 12, 2024
Automated Marketing Firm Unveils New Image Editing Suite
September 11, 2024
Israeli Renewable Energy Firm Launches First US Solar Power Project
September 11, 2024
Facebook comments